Paratek Pharmaceuticals

Investment area

Bioindustrial Investments



Date of investment

September 2023

With annual revenues of greater than $100 million, Paratek is one of the largest independent antibiotics companies in the world. Its lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is the first-choice antibiotic for patients with comorbidities or suspected resistant pathogens. Paratek’s specialty pharmaceutical platform enables both the development and commercialisation of new drugs to bring new innovative therapies to patients.

Visit site


Aleks Engel


Departments: Bioindustrial Investments, Novo Holdings Equity US Inc.

Aleks joined Novo Holdings A/S in 2014 and is Partner in the Bioindustrial investments team.
Aleks also leads Novo Holdings’ REPAIR Impact Fund targeting antimicrobial resistance.

Prior to joining Novo Holdings, Aleks was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).

Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.